Respiro

Upgrading respiratory care

amiko

Respiratory Innovation Summit
May 17, 2019 – Dallas, TX

Presented by:
Mattiènne van der Kamp
Researcher at Medisch Spectrum Twente

Chronic Respiratory Disease in the US and EU

amiko

80+ Mln diagnosed
with asthma or COPD

Adherence <35%
in all respiratory therapies

10-19% readmissions
within 30 days

$220+ Bln
in total annual costs

- Dhamane et al, 2017; Bender et al, 2006
- Harries et al, 2017Jacobs et al, 2018
- ERS White Book, 2014; Ford et al, 2015; CDC vital signs, 2011

Key pain points in the management of respiratory disease

Low adherence
and poor inhalation
technique

Self-management
is difficult and
burdensome

HCPs lack data
to optimize therapy and
prevent exacerbations

Respiro Digital Medicine

amiko

Connected medicines
Approved drug with
sensing and connectivity module

+

Digital therapy
Clinically validated software to more
effectively manage and treat chronic
respiratory disease

Modernizing the patient journey with digital

amiko

Physician
prescribes connected
drug + software

Pharmacist
gives connected
drug + software access
code to patient

Patient
uses connected drug +
software that promotes
behaviour change

Digital Platform
integrates and displays
data, for more timely
and effective treatments

# Respiro Sensors

amıko

www.rs01x.com

- Track inhaler adherence, technique and inspiratory flow data
- Sensing technology is external to drug delivery pathway
- Data is processed, encrypted and stored on on the device
- Add-ons available for Ellipta, NEXThaler, ProAir, Easyhaler, MDIs

Respiro Sensors

amiko

- Mobile personalized support help control asthma or COPD
- Promotes medication adherence and correct inhaler technique
- Coaching based on medication usage, symptoms and triggers data
- White-label applications and integration ready SDK

Respiro Vision

- Monitor trends on adherence, inhaler technique and inspiratory flow
- Identify patient at greater risk of exacerbations
- discover new insights with population data analytics
- 3rd party integrations via our APIs and custom connectors

Compelling clinical outcomes with Respiro

amiko

Improved adherence

Medication adherence %

Control: 30%
Respiro: 82%

Optimized technique

Correct inhalation technique %

Control: 31%
Respiro: 79%

Asthma Control

Asthma Control Test score

Control: 15
Respiro: 20,1

- Chan et al, 2015; Sanchis et al, 2016
- Data from Amiko's commercial pilots and clinical trials
- EIT, 2019

MAMA
a program by

- **Digital health program** designed to improve pediatric asthma care

- **Collaboration** between hospital, insurer and technology partner

- **40 patients** enrolled over a year (6 months of historic data + 6 months intervention)

- **Evaluation** based on health, quality of life and economic impact

MAMA program results

Asthma outcome measures

Medication adherence   **+52%**

Adherence %

Asthma control   **+40%**

C-ACT scores

Lung function   **+13%**

FEV 1

■ Pre-enrolment   ■ Post-enrolment

Healthcare resource utilization

ER visits   **-83%**

N° ER visits

Hospitalizations   **-100%**

N° admissions

Total healthcare cost   **-95%**

$

THANK YOU!
www.amiko.io

Upgrading respiratory care with Respiro
Respiratory Innovation Summit
May 17, 2019 – Dallas, TX

Presented by:
Mattiènne van der Kamp
Researcher at Medisch Spectrum Twente